{"id":"NCT02264574","sponsor":"Pharmacyclics LLC.","briefTitle":"A Multi-Center Study of Ibrutinib in Combination With Obinutuzumab Versus Chlorambucil in Combination With Obinutuzumab in Patients With Treatment naïve Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)","officialTitle":"A Randomized, Multi-center, Open-label, Phase 3 Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib in Combination With Obinutuzumab Versus Chlorambucil in Combination With Obinutuzumab in Subjects With Treatment-naïve Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-10-06","primaryCompletion":"2018-03-26","completion":"2019-09-03","firstPosted":"2014-10-15","resultsPosted":"2019-04-16","lastUpdate":"2020-09-21"},"enrollment":229,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Chronic Lymphocytic Leukemia","Small-Cell Lymphoma"],"interventions":[{"type":"DRUG","name":"Ibrutinib","otherNames":[]},{"type":"DRUG","name":"Obinutuzumab","otherNames":[]},{"type":"DRUG","name":"Chlorambucil","otherNames":[]}],"arms":[{"label":"IBR + OB","type":"EXPERIMENTAL"},{"label":"CLB + OB","type":"EXPERIMENTAL"}],"summary":"The primary objective of this study is to evaluate the efficacy of ibrutinib in combination with obinutuzumab compared to chlorambucil in combination with obinutuzumab based on the Independent Review Committee (IRC) assessment of progression free survival (PFS). Efficacy will be evaluated according to 2008 International Workshop for Chronic Lymphocytic Leukemia (IWCLL) criteria with the modification for treatment-related lymphocytosis, in subjects with treatment-naive CLL or SLL.","primaryOutcome":{"measure":"Primary Analysis: Progression Free Survival (PFS) Based on Independent Review Committee (IRC) Assessment - Kaplan Meier Landmark Estimates at Month 30","timeFrame":"Month 30 (Median follow-up time was 31.3 months at the time of the primary analysis [data cutoff date: 26 March 2018]).","effectByArm":[{"arm":"IBR+OB","deltaMin":78.5,"sd":null},{"arm":"CLB+OB","deltaMin":31.1,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":71,"countries":["United States","Australia","Austria","Belgium","Canada","Czechia","France","Israel","Italy","New Zealand","Poland","Russia","Spain","Sweden","Turkey (Türkiye)","United Kingdom"]},"refs":{"pmids":["30522969","40266025","35021599","35014928","34865212","34018029"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":69,"n":113},"commonTop":["Neutropenia","Infusion related reaction","Thrombocytopenia","Diarrhea","Nausea"]}}